Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunovant (IMVT) Notes Payables (2018 - 2019)

Immunovant filings provide 2 years of Notes Payables readings, the most recent being $300000.0 for Q1 2019.

  • Quarterly Notes Payables changed N/A to $300000.0 in Q1 2019 from the year-ago period, while the trailing twelve-month figure was $300000.0 through Mar 2019, changed N/A year-over-year, with the annual reading at $300000.0 for FY2019, N/A changed from the prior year.
  • Notes Payables hit $300000.0 in Q1 2019 for Immunovant, roughly flat from $300000.0 in the prior quarter.
  • Across five years, Notes Payables topped out at $300000.0 in Q4 2018 and bottomed at $300000.0 in Q4 2018.